Bavarian Nordic Q2 EBITDA Loss Smaller Than Expected

• (PLX AI) - Bavarian Nordic Q2 revenue DKK 537 million vs. estimate DKK 547 million.
• • Q2 EBITDA DKK -118 million vs. estimate DKK -127 million
• • Outlook FY revenue DKK 2,700-2,900 million (unchanged from July 18)
• • Says making every effort to meet the initial worldwide demand for our monkeypox vaccine and are working diligently to further expand our manufacturing capacity through additional scale-up activities and partnerships
• • Says nearing a break-even result for 2022, and we see a robust business for the monkeypox vaccine building up beyond 2022